Brief: An2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole For Treatment-Refractory Mac Lung Disease
29/06/2022 12:04
June 29 (Reuters) - AN2 Therapeutics Inc ANTX.O :
* AN2 THERAPEUTICS INITIATES PIVOTAL PHASE 2/3 TRIAL
EVALUATING
EPETRABOROLE FOR TREATMENT-REFRACTORY MAC LUNG DISEASE
* AN2 THERAPEUTICS - PHASE 2/3 PIVOTAL TRIAL EXPECTED TO
SUPPORT
REGULATORY APPROVAL FOR TREATMENT-REFRACTORY MAC LUNG DISEASE;
PLAN TO USE LPAD PATHWAY
Source text for Eikon: ID:nGNX3nqkgl
Further company coverage: ANTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview